Vera Therapeutics Inc. (NASDAQ:VERA) stock rose Wednesday after the U.S. Food and Drug Administration (FDA) accepted the company’s atacicept Biologics License Application (BLA) for Priority Review.The application covers adults with immunoglobulin A nephropathy (IgAN).IgAN is an autoimmune disease of the kidney. In at least 50% of patients, IgAN can lead to end-stage kidney disease or kidney failure.Atacicept is being developed as an at-home self-administered subcutaneous once-weekly injection that inhibits ...